CHEST 2003.

Methods	No use of lipid‐lowering agents in the 6 months before enrolment 12‐Week before‐and‐after study
Participants	80 men and women from the USA aged > 18 years 2 participants failed to return for follow‐up blood testing; therefore 78 participants were included in the analysis 30 participants received atorvastatin, 21 received simvastatin, 27 received pravastatin Exclusion criteria: CHD history, hepatic dysfunction, statin intolerance history, alcohol or drug abuse, major illness, surgery, malignancy, pregnancy threat Atorvastatin baseline TC: 6.15 mmol/L (238 mg/dL) Atorvastatin baseline LDL‐C: 4.08 mmol/L (158 mg/dL) Atorvastatin baseline HDL‐C: 1.22 mmol/L (47 mg/dL) Atorvastatin baseline TG: 2.05 mmol/L (182 mg/dL)
Interventions	Atorvastatin 10 mg/d Simvastatin 20 mg/d Pravastatin 40 mg/d
Outcomes	Per cent change from baseline at 12 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	Atorvastatin group was analysed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	Low risk	The study appears to be free of other sources of bias